<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934335</url>
  </required_header>
  <id_info>
    <org_study_id>201301763</org_study_id>
    <nct_id>NCT01934335</nct_id>
  </id_info>
  <brief_title>Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ronald Weigel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to examine whether treatment with vandetanib has an effect on&#xD;
      the tumor cells in breast cancer by examining tissue markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to test whether vandetanib has an effect on tumor&#xD;
      growth markers. Vandetanib is not approved by the FDA for use in treating breast cancer. This&#xD;
      study will compare vandetanib to a placebo.&#xD;
&#xD;
      The proposed study is designed to determine the change in Ki-67 expression on paired breast&#xD;
      cancer samples obtained before and after treatment with vandetanib. Other tumor markers&#xD;
      including RET, TUNEL and phosphorylation specific levels of ERK1/2, AKT and mTOR will also be&#xD;
      assessed on the paired samples.&#xD;
&#xD;
      Those who have a core biopsy of the breast which demonstrates invasive breast cancer and&#xD;
      requires surgical excision of the lesion will be eligible for inclusion in the study. The&#xD;
      tyrosine kinase inhibitor, vandetanib 300 mg, will be given once a day for 7-14 days prior to&#xD;
      surgery. Following surgery, tissue markers would be analyzed on each of the paired samples,&#xD;
      allowing for rapid assessment of in vivo response to TKI treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drugs unavailable&#xD;
  </why_stopped>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for Ki-67.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for TUNEL.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in RET Expression Observed 2 Weeks Post-treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Results will be stratified by RET gene expression, a negative prognostic indicator in breast cancer, to demonstrate that RET is a marker of response.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Invasive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, PO, q day for 7-14 days prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <arm_group_label>Vandetanib</arm_group_label>
    <other_name>ZD6474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with core breast biopsy that, on pathology review, demonstrates invasive&#xD;
             breast cancer and are determined to need surgical excision of the lesion. All subtypes&#xD;
             of invasive breast cancer will be enrolled. Core biopsy specimens of enrolled patients&#xD;
             will be stained for RET by immunohistochemistry and scored, however, patients will not&#xD;
             be excluded according to RET expression.&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Age &gt;/= 18 years of age&#xD;
&#xD;
          -  ECOG performance status &lt;/= 2&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
          -  Ability and willingness to provide informed consent to participate in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prolonged QT interval (QTc &gt; 480 milliseconds) on screening EKG or congenital long QT&#xD;
             syndrome&#xD;
&#xD;
          -  Any concomitant medications that are known to be associated with Torsades de Pointes&#xD;
             or QT elongation (see appendix 2).&#xD;
&#xD;
          -  Hypertension not controlled by medical therapy (systolic BP greater than 160&#xD;
             millimeters of mercury [mmHg] or diastolic blood pressure great than 100 mmHg).&#xD;
&#xD;
          -  Patients taking metformin or digoxin.&#xD;
&#xD;
          -  History of arrhythmia (multifocal premature ventricular contractions, bigeminy,&#xD;
             trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE&#xD;
             Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or&#xD;
             asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation&#xD;
             controlled by medication are permitted.&#xD;
&#xD;
          -  Significant cardiac event (e.g., myocardial infarction), superior vena cava syndrome,&#xD;
             New York Heart Association (NYHA) classification of heart disease â‰¥2 within 12 weeks,&#xD;
             or presence of cardiac disease that in the opinion of the Investigator increases the&#xD;
             risk of ventricular arrhythmia.&#xD;
&#xD;
          -  Serum calcium or magnesium outside the institutional range of normal.&#xD;
&#xD;
          -  Serum Potassium &lt; 4.0 mmol/L or above 5.0 mmol/L&#xD;
&#xD;
          -  Creatinine clearance &lt; 50 ml/min&#xD;
&#xD;
          -  PT &gt; 12 seconds or PTT &gt; 31 seconds&#xD;
&#xD;
          -  Platelet count of &lt; 100,000&#xD;
&#xD;
          -  Serum bilirubin greater than 1.5 mg/dl&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; 50 U/L, aspartate aminotransferase (AST) &gt; 65 U/L, or&#xD;
             alkaline phosphatase (ALP) &gt; 250 U/L&#xD;
&#xD;
          -  Any cytotoxic treatments, such as neoadjuvant chemotherapy, planned before subsequent&#xD;
             surgical procedure.&#xD;
&#xD;
          -  Previous exposure to Vandetanib&#xD;
&#xD;
          -  Previous enrollment or randomization in this study&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and staff at UIHC).&#xD;
&#xD;
          -  Previous or current malignancies of other histologies within the last 5 years, with&#xD;
             the exception of in situ carcinoma of the cervix, and adequately treated basal cell or&#xD;
             squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Patients who have received prior surgical site radiation.&#xD;
&#xD;
          -  Patients on CYP3A4 inhibitors or inducers (see appendix 1).&#xD;
&#xD;
          -  Inability to test core biopsy for study markers&#xD;
&#xD;
          -  Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be&#xD;
             performed within 2 weeks prior to randomization according to institutional standards&#xD;
             for women of childbearing potential.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronal Weigel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <results_first_submitted>May 13, 2021</results_first_submitted>
  <results_first_submitted_qc>October 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2021</results_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Ronald Weigel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer, TKI, tyrosine kinase inhibitor, vandetanib, Ki-67</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01934335/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01934335/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vandetanib</title>
          <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery&#xD;
Vandetanib</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, PO, q day for 7-14 days prior to surgery.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who have a core biopsy of the breast which demonstrates invasive breast cancer and require surgical excision of the lesion are eligible for inclusion in the study</population>
      <group_list>
        <group group_id="B1">
          <title>Vandetanib</title>
          <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery&#xD;
Vandetanib</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, PO, q day for 7-14 days prior to surgery.&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" lower_limit="35.5" upper_limit="71.1"/>
                    <measurement group_id="B2" value="62.9" lower_limit="45.4" upper_limit="72.5"/>
                    <measurement group_id="B3" value="58.8" lower_limit="35.5" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment</title>
        <description>Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for Ki-67.</description>
        <time_frame>2 weeks</time_frame>
        <population>10 subjects took study drug and completed surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib</title>
            <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery&#xD;
Vandetanib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, PO, q day for 7-14 days prior to surgery.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment</title>
          <description>Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for Ki-67.</description>
          <population>10 subjects took study drug and completed surgery</population>
          <units>percentage of positivity for Ki-67.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.08"/>
                    <measurement group_id="O2" value="2" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment</title>
        <description>Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for TUNEL.</description>
        <time_frame>2 weeks</time_frame>
        <population>10 subjects took study drug and completed surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib</title>
            <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery&#xD;
Vandetanib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, PO, q day for 7-14 days prior to surgery.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment</title>
          <description>Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for TUNEL.</description>
          <population>10 subjects took study drug and completed surgery</population>
          <units>percentage of for positivity for TUNEL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.71"/>
                    <measurement group_id="O2" value="1.02" spread="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in RET Expression Observed 2 Weeks Post-treatment</title>
        <description>Results will be stratified by RET gene expression, a negative prognostic indicator in breast cancer, to demonstrate that RET is a marker of response.</description>
        <time_frame>2 weeks</time_frame>
        <population>6 patients that got the study drug and completed surgery by RET expression were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib</title>
            <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery&#xD;
Vandetanib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, PO, q day for 7-14 days prior to surgery.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in RET Expression Observed 2 Weeks Post-treatment</title>
          <description>Results will be stratified by RET gene expression, a negative prognostic indicator in breast cancer, to demonstrate that RET is a marker of response.</description>
          <population>6 patients that got the study drug and completed surgery by RET expression were analyzed</population>
          <units>percent change of RET positive samples</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ki-67</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.03"/>
                    <measurement group_id="O2" value="1.0" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUNEL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.32"/>
                    <measurement group_id="O2" value="0.2" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vandetanib</title>
          <description>Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery&#xD;
Vandetanib</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, PO, q day for 7-14 days prior to surgery.&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Itchy eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Weigel, MD, PhD</name_or_title>
      <organization>Holden Comprehensive Cancer Center</organization>
      <phone>319-353-7474</phone>
      <email>ronald-weigel@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

